Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces Boulardii vs Rifaximin in SIBO
NCT07815548Phase 4Not yet recruiting
- Sponsor
- Shandong University
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 4 trial of saccharomyces boulardii in small intestinal bacterial overgrowth (SIBO), sponsored by Shandong University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT07815548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815548.